Epigenetics Market Players:
- AbbVie
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche
- GlaxoSmithKline (GSK)
- Incyte
- Jazz Pharmaceuticals
- Merck & Co.
- Novartis
- Pfizer
- Bio-Techne
- Merck KGaA
Several large drug companies include epigenetics studies within their wider cancer or other health issue programs. Moreover, a few smaller firms dedicate their entire focus to epigenetics. These efforts reflect the rapidly evolving nature of the field and its significant potential for transforming therapeutic approaches, underscoring the critical role of both large and small entities in advancing our understanding and treatment of diseases through epigenetic science.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of epigenetics is evaluated at USD 2.82 billion.
The global epigenetics market size was worth over USD 2.52 billion in 2025 and is poised to grow at a CAGR of more than 13.1%, reaching USD 8.63 billion revenue by 2035.
North America epigenetics market will dominate more than 47% share by 2035, driven by rising cancer rates, health tech usage, and pharma innovation.
Key players in the market include Illumina, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Abcam plc, QIAGEN N.V., Zymo Research Corporation, Diagenode SA (Hologic), Active Motif, Inc., Epigentek Group Inc., Bio-Rad Laboratories, Inc.
